tiprankstipranks
Fine Foods & Pharmaceuticals N.T.M. SpA (IT:FF)
:FF
Italy Market
Want to see IT:FF full AI Analyst Report?

Fine Foods & Pharmaceuticals N.T.M. SpA (FF) AI Stock Analysis

8 Followers

Top Page

IT:FF

Fine Foods & Pharmaceuticals N.T.M. SpA

(FF)

Select Model
Select Model
Select Model
Neutral 50 (OpenAI - 5.2)
Rating:50Neutral
Price Target:
€9.00
▼(-4.26% Downside)
Action:ReiteratedDate:03/24/26
The score is held back primarily by weakening cash-flow quality (negative 2025 free cash flow), margin volatility (sharp 2025 gross margin drop), and a bearish technical setup (below all key moving averages with negative MACD). These are partially offset by the earnings recovery and modest shareholder yield.
Positive Factors
CDMO business model
FF's contract development and manufacturing focus creates repeatable, B2B revenue streams and deep client relationships across nutraceutical and pharmaceutical customers. Regulatory capability and specialized production act as structural barriers, supporting durable demand and revenue resilience over months.
Negative Factors
Sharp gross margin deterioration
A dramatic gross margin collapse implies structural issues in pricing, input costs, product mix, or one-off charges. Such a drop materially erodes core profitability and makes operating margins fragile; if persistent, it will reduce cash generation and return on invested capital.
Read all positive and negative factors
Positive Factors
Negative Factors
CDMO business model
FF's contract development and manufacturing focus creates repeatable, B2B revenue streams and deep client relationships across nutraceutical and pharmaceutical customers. Regulatory capability and specialized production act as structural barriers, supporting durable demand and revenue resilience over months.
Read all positive factors

Fine Foods & Pharmaceuticals N.T.M. SpA (FF) vs. iShares MSCI Italy ETF (EWI)

Fine Foods & Pharmaceuticals N.T.M. SpA Business Overview & Revenue Model

Company Description
Fine Foods & Pharmaceuticals N.T.M. S.p.A. engages in the contract development and manufacturing of oral solid forms for the pharmaceutical and nutraceutical industries. It offers pharmaceutical products, including powders and granules, capsules, ...
How the Company Makes Money
The company makes money by providing contract manufacturing services to customers in the nutraceutical and pharmaceutical sectors. FF generates revenue by producing and packaging products per client specifications. They may also earn income from p...

Fine Foods & Pharmaceuticals N.T.M. SpA Financial Statement Overview

Summary
Earnings have recovered with steady EBIT margins (~6%) and improving net margin (~4% in 2025), but the profile is weakened by negative/flat revenue trend, a sharp 2025 gross margin deterioration, rising leverage (debt-to-equity ~0.65), and a swing to negative free cash flow in 2025.
Income Statement
63
Positive
Balance Sheet
58
Neutral
Cash Flow
46
Neutral
BreakdownDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue252.06M243.75M251.81M206.85M194.42M
Gross Profit16.53M80.13M68.56M53.63M55.89M
EBITDA34.43M30.90M19.29M3.64M9.86M
Net Income10.10M8.16M-3.52M-9.50M-1.43M
Balance Sheet
Total Assets280.02M242.59M241.56M299.82M302.81M
Cash, Cash Equivalents and Short-Term Investments38.88M19.21M19.15M76.74M95.09M
Total Debt86.78M54.53M66.39M120.36M110.76M
Total Liabilities145.82M110.53M114.61M166.53M155.59M
Stockholders Equity134.21M132.06M126.95M133.29M147.22M
Cash Flow
Free Cash Flow-2.87M11.12M-329.75K-12.30M-21.75M
Operating Cash Flow31.76M45.85M18.54M3.69M-5.83M
Investing Cash Flow-35.85M-31.56M45.89M-15.31M-36.35M
Financing Cash Flow23.76M-14.08M-55.66M4.74M55.95M

Fine Foods & Pharmaceuticals N.T.M. SpA Technical Analysis

Technical Analysis Sentiment
Positive
Last Price9.40
Price Trends
50DMA
9.85
Negative
100DMA
9.75
Negative
200DMA
9.22
Positive
Market Momentum
MACD
-0.20
Negative
RSI
57.04
Neutral
STOCH
88.73
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IT:FF, the sentiment is Positive. The current price of 9.4 is above the 20-day moving average (MA) of 8.45, below the 50-day MA of 9.85, and above the 200-day MA of 9.22, indicating a neutral trend. The MACD of -0.20 indicates Negative momentum. The RSI at 57.04 is Neutral, neither overbought nor oversold. The STOCH value of 88.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IT:FF.

Fine Foods & Pharmaceuticals N.T.M. SpA Peers Comparison

Overall Rating
UnderperformOutperform
Sector (62)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
62
Neutral
$20.33B14.63-3.31%3.23%1.93%-12.26%
61
Neutral
€113.24M14.769.28%3.53%0.94%-3.35%
50
Neutral
€223.89M24.251.48%3.41%23.12%
* Consumer Defensive Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
IT:FF
Fine Foods & Pharmaceuticals N.T.M. SpA
9.24
2.12
29.85%
IT:VLS
Valsoia SpA
10.55
0.05
0.46%
IT:ENV
Enervit S.p.A.
4.73
1.57
49.68%
IT:HQF
High Quality Food SpA
0.51
-0.07
-11.71%
IT:IWB
Italian Wine Brands S.p.A.
20.25
0.04
0.20%
IT:NWL
NewPrinces S.p.A.
17.71
0.87
5.17%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Mar 24, 2026